Non-relevance of acute dermal toxicity testing for assessing human health protection in the regulatory decision-making for agrochemical formulated products.
Autor: | Latorre AO; Bayer S.A., Rua Domingos Jorge, 1100, Sao Paulo, SP, Brazil. Electronic address: andreia.latorre@bayer.com., Floresta PVM; Corteva, Alameda Itapecuru, 506, Alphaville, Barueri, SP, Brazil., Boff MM; IHARABRAS S.A. INDUSTRIAS QUIMICAS, Avenida Liberdade, Sorocaba, SP, Brazil., Fagundes PM; Syngenta Crop Protection, Avenida das Nacoes Unidas, 18001, Sao Paulo, SP, Brazil., Martins AP; FMC Química do Brasil LTDA, Av. Dr. Jose Bonifacio Coutinho Nogueira, 150, Campinas, SP, Brazil., Ihlaseh-Catalano SM; BASF S.A., Avenida das Nacoes Unidas, 12997, 17279, Sao Paulo, SP, Brazil., Cazarin KCC; BASF S.A., Avenida das Nacoes Unidas, 12997, 17279, Sao Paulo, SP, Brazil., Romeo LL; Bayer S.A., Rua Domingos Jorge, 1100, Sao Paulo, SP, Brazil. |
---|---|
Jazyk: | angličtina |
Zdroj: | Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2019 Aug; Vol. 106, pp. 105-110. Date of Electronic Publication: 2019 Apr 25. |
DOI: | 10.1016/j.yrtph.2019.04.014 |
Abstrakt: | Compared to oral toxicity tests, dermal toxicity tests offer little or no additional scientific information or public health protection for agrochemical-formulated products (US EPA, 2016). Based on that, a retrospective analysis of the results of acute oral and dermal LD (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |